JP-2022537178-A5 -

Dates

Publication Date

20230509

Application Date

20200617

Description

[Invention 1001]A method for treating chronic obstructive pulmonary disease (COPD) in a mammal, comprising administering to the mammal a composition comprising live or dead Prevotella.[Invention 1002]The method of the present invention 1001, wherein the composition contains living Prevotella.[Invention 1003]The method of the present invention 1001, wherein the composition contains dead Prevotella but does not contain live Prevotella.[Invention 1004]Any method 1001 to 1003 of the present invention, wherein the administration includes oral administration.[Invention 1005]A method according to any one of the present invention 1001 to 1003, wherein the administration includes administration to the respiratory system.[Invention 1006]The method according to any one of the present invention 1001 to 1005, whereinthe composition contains about 1 × 10³toabout 1 ×10¹⁴ CFU of prevotera. [Invention 1007] The method according to any one of the present invention 1001 to 1006, wherein the Prevotella comprises Prevotella histicola. [Invention 1008] A non-human mammalian model of chronic obstructive pulmonary disease (COPD), wherein the somatic cells of the non-human mammalian model contain nucleic acids encoding one or more human HLA serotypes, the somatic cells of the non-human mammalian model lack expression of endogenous MHC class II molecules and endogenous IL-17 polypeptides, and when exposed to tobacco smoke for about 2 to about 6 weeks, the lung function of the model is reduced compared to a comparable model that has not been exposed to tobacco smoke. [Invention 1009] A non-human mammalian model of the present invention 1034, wherein the aforementioned human HLA serotype is DQ8. [Invention 1010] A non-human mammalian model of the present invention 1009, which is an IL-17 -/- knockout mammal. [Invention 1011] A method for creating a non-human mammalian model of chronic obstructive pulmonary disease (COPD), comprising the following steps: A step of providing a non-human mammal, wherein the somatic cells of the non-human mammal contain nucleic acids encoding one or more human HLA serotypes, and the somatic cells of the non-human mammal model lack the expression of endogenous MHC class II molecules and endogenous IL-17 polypeptides; and A process for creating a non-human animal model of COPD by exposing the mammal to tobacco smoke for approximately 3 to 6 weeks. [Invention 1012] A method for treating a pulmonary condition in a mammal, comprising administering to the mammal a composition containing live or dead Prevotella. [Invention 1013] The method of the present invention 1012, wherein the composition comprises about 1 × 10³ to about 1 × 10¹⁴ CFU of prevotera. [Invention 1014] The method according to any one of the present invention 1012 to 1013, wherein the Prevotella includes Prevotella histicola. [Invention 1015] The method according to any one of items 1012 to 1014 of the present invention, wherein the lung condition is selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, sarcoidosis, disease caused by infection, and combinations thereof. [Invention 1016] The method of the present invention 1015, wherein the disease caused by infection is selected from the group consisting of viral infections, bacterial infections, fungal infections, parasitic infections, and combinations thereof. [Invention 1017] The method of the present invention 1016, wherein the viral infection is selected from the group consisting of viral pneumonia, viral bronchitis, influenza, coronavirus infection, adenovirus infection, syncytial virus infection, rhinovirus infection, and combinations thereof. [Invention 1018] A method for treating a pulmonary condition in a mammal, comprising administering to the mammal a composition comprising live or dead Prevotella melaninogenica. [Invention 1019] The method of the present invention 1018, wherein the composition comprises living Prevotella melaninogenica. [Invention 1020] The method of the present invention 1018, wherein the composition contains dead Prevotella melaninogenica but does not contain live Prevotella melaninogenica. [Invention 1021] The method according to any one of the present invention 1018 to 1020, wherein the composition comprises about 1 × 10³ to about 1 × 10¹⁴ CFU of Prevotella melaninogenica. [Invention 1022] The method according to any one of items 1018 to 1021 of the present invention, wherein the lung condition is selected from the group consisting of chronic obstructive pulmonary disease (COPD), asthma, pulmonary fibrosis, sarcoidosis, disease caused by infection, and combinations thereof. [Invention 1023] The method of the present invention 1022, wherein the disease caused by infection is selected from the group consisting of viral infections, bacterial infections, fungal infections, parasitic infections, and combinations thereof. [Invention 1024] The method of the present invention 1023, wherein the viral infection is s